<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644941</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-PRO-V006</org_study_id>
    <secondary_id>2015-003261-28</secondary_id>
    <nct_id>NCT02644941</nct_id>
  </id_info>
  <brief_title>Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis</brief_title>
  <official_title>An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humacyte, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CTI Clinical Trial and Consulting Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Humacyte, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE
      grafts when used for hemodialysis access.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, prospective, multicenter, multinational, open-label, randomized, two-arm,
      comparative study. Subjects who sign informed consent would undergo study-specific screening
      assessments within 35 days from the day of informed consent.

      On the day of surgery (Day 0), subjects could still be undergoing screening assessments, such
      as confirmation of inclusion/exclusion criteria, to determine their eligibility before they
      are randomized in the study. Eligible study subjects will be randomized to receive either a
      HAV or one of two commercially available ePTFE grafts and followed to 24 months
      post-implantation at routine study visits regardless of patency status. After 24 months,
      subjects with a patent study conduit will be followed (while the study conduit remains
      patent) for up to 5 years (60 months) post implantation at routine study visits.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 24, 2016</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to loss of Secondary Patency from implantation</measure>
    <time_frame>12 months post-implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to loss of Secondary Patency from implantation</measure>
    <time_frame>24 &amp; 60 months post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of Primary Patency from implantation</measure>
    <time_frame>12, 24, &amp; 60 months post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access-related infections</measure>
    <time_frame>12, 24, &amp; 60 months post-implantation</time_frame>
    <description>Using Dialysis Event Surveillance Manual: CDC; 2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of interventions required to achieve/maintain Secondary Patency</measure>
    <time_frame>12, 24, &amp; 60 months post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of Primary Assisted Patency from implantation</measure>
    <time_frame>12, 24, &amp; 60 months post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological remodeling of any study conduit</measure>
    <time_frame>12, 24, &amp; 60 months post-implantation</time_frame>
    <description>Microscopic examination of explanted conduit for cellular infiltration and extracellular remodeling processes, including neo-synthesis and reorganization of ECM components (descriptive summaries only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The efficiency of dialysis as assessed by spKt/Vurea (subset of subjects)</measure>
    <time_frame>12 &amp; 24 months post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of AEs</measure>
    <time_frame>12 &amp; 24 months post-implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>True aneurysm formation (conduit lumen diameter &gt;9mm)</measure>
    <time_frame>12, 24, &amp; 60 months post-implantation</time_frame>
    <description>Assessed by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pseudoaneurysm formation</measure>
    <time_frame>12, 24, &amp; 60 months post-implantation</time_frame>
    <description>Assessed by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study conduit rupture</measure>
    <time_frame>12, 24, &amp; 60 months post-implantation</time_frame>
    <description>Assessed by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anastomotic bleeding or rupture</measure>
    <time_frame>12, 24, &amp; 60 months post-implantation</time_frame>
    <description>Assessed by ultrasound</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">355</enrollment>
  <condition>Renal Failure</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Hemodialysis</condition>
  <condition>Vascular Access</condition>
  <arm_group>
    <arm_group_label>Human Acellular Vessel (HAV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ePTFE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparator (one of two commercially available 6mm ePTFE grafts) will be surgically implanted in the forearm or upper arm on Study Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Acellular Vessel (HAV)</intervention_name>
    <description>Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.</description>
    <arm_group_label>Human Acellular Vessel (HAV)</arm_group_label>
    <other_name>(regulated as a biological product)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ePTFE graft</intervention_name>
    <description>Surgical implantation of a commercially available ePTFE graft and subsequent use of the implanted vascular conduit for hemodialysis vascular access.</description>
    <arm_group_label>ePTFE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with ESRD who are not, or who are no longer, candidates for creation of an
             autologous AV fistula and therefore need placement of an AV graft in the arm (upper-
             or forearm) to start or maintain hemodialysis therapy.

          -  Either on hemodialysis or expected to start hemodialysis within 12 weeks of study
             conduit implantation.

          -  At least 18 years of age at Screening.

          -  Suitable anatomy for implantation of straight or looped conduits in either the forearm
             or upper arm (not crossing the elbow).

          -  Hemoglobin ≥8 g/dL and platelet count ≥100,000 cells/mm3 prior to Day 0 (within 35
             days).

          -  Other hematological and biochemical parameters within a range consistent with ESRD
             prior to Day 0 (within 35 days).

          -  Adequate liver function prior to Day 0 (within 35 days), defined as:

               -  ≤2x upper limit of normal (ULN) for serum bilirubin, aspartate transaminase
                  (AST), alanine transaminase (ALT), and alkaline phosphatase

               -  ≤1.5 for International Normalized Ratio (INR) or prothrombin time (PT) ≤ 18
                  seconds unless the subject is taking an anticoagulant at the time

          -  Female subjects must be either:

               -  Of non-childbearing potential, which is defined as post-menopausal (at least 1
                  year without menses prior to Screening) or documented surgically sterile or post
                  hysterectomy (at least 1 month prior to Screening)

               -  Or, of childbearing potential, in which case:

                    -  Must have a negative urine pregnancy test at Screening, and

                    -  Must agree to use at least one form of the following birth control methods
                       for the duration of the study:

                         -  Established use of oral, injectable or implanted hormonal methods of
                            contraception

                         -  Placement of an intrauterine device or intrauterine system

                         -  Barrier methods of contraception: condom or occlusive cap (diaphragm or
                            cervical/vault caps) with spermicidal foam/ gel/ film/ cream/
                            suppository

          -  Subject, or legal representative, able to communicate effectively with investigative
             staff, competent and willing to give written informed consent, and able to comply with
             entire study procedures including all scheduled follow-up visits.

          -  Life expectancy of at least 1 year.

        Exclusion Criteria:

          -  History or evidence of severe peripheral vascular disease in the intended arm for
             implantation.

          -  Known or suspected central vein obstruction on the side of planned implantation,
             unless corrected before study conduit implantation.

          -  Treatment with any investigational drug or device within 60 days prior to study entry
             (Day 0) or ongoing participation in a clinical trial of an investigational product.

          -  Cancer that is actively being treated with a cytotoxic agent.

          -  Documented hyper-coagulable state.

          -  Bleeding diathesis.

          -  Active clinically significant autoimmune disease.

          -  Anticipated renal transplant within 6 months.

          -  Venous outflow from study conduit cannot be placed more centrally than any previous
             failed access.

          -  Active local or systemic infection (white blood cells [WBC] &gt; 15,000 cells/mm3 at
             Screening). If the infection resolves, the subject must be at least one week post
             resolution of that infection before implantation.

          -  Known serious allergy to planned antiplatelet agent.

          -  Pregnant women, or women intending to become pregnant during the course of the trial.

          -  Any other condition which in the judgment of the investigator would preclude adequate
             evaluation of the safety and efficacy of the study conduit.

          -  Previous enrollment in this study or any other study with the HAV.

          -  Employees of Humacyte and employees or relatives of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey H Lawson, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Humacyte, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Kidney Disease and Hypertension Center (AKDHC)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carondelet St. Mary's Hospital</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ladenheim Dialysis Access Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacramento VA Medical Center</name>
      <address>
        <city>Mather</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Balboa Nephrology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Vascular Access Center</name>
      <address>
        <city>Alsip</city>
        <state>Illinois</state>
        <zip>60803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Shore Medical Center</name>
      <address>
        <city>Easton</city>
        <state>Maryland</state>
        <zip>21601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Vascular Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenwood Leflore Hospital</name>
      <address>
        <city>Greenwood</city>
        <state>Mississippi</state>
        <zip>38930</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers University</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Medical Center</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Regional Medical Center</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Vascular Associates / Baylor</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikmn Erlangen, Gefäßchirurgie - Chirurgisches Zentrum</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt Klinik für Gefäß- und Endovascular-Chirurgie</name>
      <address>
        <city>Frankfurt/Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Jaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <state>Haifa</state>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Aviv</state>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharee Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Tzrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Chirurgii Naczyń i Angiologii Uniwersytetu Medycznego w Lublinie</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego</name>
      <address>
        <city>Poznan</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczyn Centralny Szpital Klinziczny</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddzial Chirurgii Naczyniowej Wojewódzki Szpital Specjalistyczny we Wrocławiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Prelada</name>
      <address>
        <city>Porto</city>
        <zip>4250-449</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <state>East Midlands/ Leicestershire</state>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy´s Hospital, Kings´College London</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham QE Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

